R 2 = 13.7% with peak C-peptide alone, R 2 = 20.4% with timing of the peak added). Similar associations were seen between the 2-hour glucose and the C-peptide measures.
Conclusions: These findings show that the addition of timing measures of C-peptide responsiveness better explains HbA1c variation at diagnosis than standard measures alone.
K E Y W O R D S
C-peptide, glycemia, HbA1c, OGTT, type 1 diabetes
| INTRODUCTION
The area under the curve (AUC) C-peptide and peak C-peptide, commonly employed measures of overall C-peptide levels during oral glucose tolerance tests (OGTTs), have been used as markers of β-cell function in the peri-diagnostic period of type 1 diabetes (T1D). However, it is unclear whether such measures are optimal, as they do not take insulin secretory patterns into account. Measures of the timing of C-peptide responsiveness have been shown to change during the progression to T1D. 1 In that report, the early (30-0 minute) C-peptide response progressively declined from approximately 2 years prior to until the time of diagnosis, while the late ([60 + 90 + 120 minute Cpeptide]−30 minutes) C-peptide response progressively increased. 1 However, to our knowledge, no studies have yet described the timing of C-peptide responses at diagnosis and how this timing may relate to glycemia. Thus, our objective in this report was to examine associations of glycemia, primarily as indicated by HbA1c, with measures of the timing of C-peptide responsiveness at the diagnosis of T1D.
Moreover, we sought to determine whether the addition of those timing measures to standard overall C-peptide measures (such as the AUC C-peptide) in multivariable models helps to explain HbA1c variance.
It has been difficult to assess C-peptide responsiveness at diagnosis in the community, as insulin is almost always administered at that time, and may interfere with endogenous insulin secretory patterns.
However, data from the Diabetes Prevention Trial-Type 1 (DPT-1)
provides the opportunity for such assessments. In that study, a large proportion of individuals were diagnosed by OGTT, prior to the clinical administration of insulin; many also had HbA1c measurements at diagnosis. We have, therefore, utilized these features of DPT-1 to improve our understanding of how glycemia relates to C-peptide responsiveness at diagnosis.
| METHODS
The DPT-1 study has been previously described. 2 Participants (relatives of persons with T1D, ages 1-45 years) were monitored with 2-hour OGTTs bi-annually for diagnosis of diabetes. ADA criteria for the diagnosis of diabetes were used for the interpretation of OGTTs.
3
Glucose and C-peptide were measured fasting and every 30 minutes.
If an OGTT was in the diabetic range, a confirmatory OGTT was performed (unless otherwise contraindicated). The date of diagnosis was based on the first OGTT, which was used for the following analyses.
DPT-1 participants (n = 85) <18.0 years of age at diagnosis with complete OGTT data and a HbA1c measurement performed simultaneously at diagnosis were included in the analysis. C-peptide and glucose assays were performed as previously described. 2 Associations between HbA1c and OGTT C-peptide indices at diagnosis were assessed through correlation and multivariable regression. To examine the association of HbA1c with the timing of Cpeptide secretion, early and late C-peptide responses were utilized, as previously described. 1 The ratio of the 120-minute over 30 minutes C-peptide (120/30 C-peptide) and timing of the peak C-peptide (occurring at ≤60 vs >60 minutes) were used as measures of relative timing.
Multivariable linear regression models were utilized to determine whether adding measures of relative timing of C-peptide responsiveness would better account for HbA1c variance than overall C-peptide indices. Because body mass index (BMI) z-score and age are known to influence C-peptide responses, 4 linear regression analyses were performed with BMI z-score and age included as covariates.
The likelihood ratio test was utilized to test the statistical significance of the contribution to the R 2 from adding C-peptide covariates to linear regression models. Squared partial correlations were used to examine the individual contributions of the covariates in explaining HbA1c variance. Please note that although the sum of partial correlations and the overall R 2 of a model can be similar in multivariable models, they are not identical.
| RESULTS
The mean (±SD) age of participants was 11.2 ± 3.3 years and the BMI z-score was 0.4 ± 1.1; 51% were male. HbA1c values at diagnosis averaged 43.54 ± 8.46 mmol/mol (6.1 ± 0.8%). Metabolic characteristics of the participants at diagnosis are indicated in Table 1 .
| Associations of HbA1c with overall C-peptide responses
HbA1c was inversely correlated with measures of overall C-peptide responsiveness: AUC C-peptide (r = −0.34; P < 0.001); peak Cpeptide (r = −0.37; P < 0.001).
| HbA1c associations after partitioning the timing of C-peptide responses
There were significant inverse correlations of HbA1c with both the early and late C-peptide responses (r = −0.34 and −0.38, respectively; P < 0.001 for both), Table 2 . These associations are demonstrated in 3.4 | The use of the timing of the C-peptide response to account for HbA1c variance
We utilized multivariable regression models to assess whether adding measures of the timing of C-peptide responsiveness would better account for HbA1c variance. Table 3 shows overall and partial 3.5 | Associations of the 2-hour glucose with C-peptide measures
As HbA1c values at diagnosis were indicative of glycemia for several months prior to diagnosis, we assessed whether the association of glycemia with the timing of the C-peptide response was also evident within the same OGTT at diagnosis. Associations were therefore examined between the 2-hour glucose (designated as the measure of glycemia post-glucose load) and C-peptide indices. Similar to HbA1c, the 2-hour glucose correlated inversely with both early and late C- Abbreviations: AUC, area under the curve; BMI, body mass index; HbA1c, hemoglobin A1c. *P ≤ 0.01. **P ≤ 0.001 for contribution to the R 2 from the addition of the second term in each model. overall measures, appreciably more HbA1c variance was explained.
The lower HbA1c values associated with a greater late C-peptide response, a higher 120/30 C-peptide, and a peak C-peptide occurring after 60 minutes suggest the importance of maintaining insulin secretion during the latter part of the OGTT, and the need for its quantitative assessment. The AUC C-peptide and the peak C-peptide do not specifically capture this important aspect of β-cell function. We also observed appreciable associations between the 2-hour glucose and the C-peptide timing measures. These findings are relevant, since the 2-hour glucose is a major diagnostic criterion for T1D.
Our findings also showed that besides the specific effect of adding C-peptide timing indices to overall measures, timing indices can provide appreciable information with regard to glycemia even in the absence of overall measures (ie, AUC and peak C-peptide levels).
The combination of the early C-peptide response and the 120/30 Cpeptide in a model resulted in an appreciable R 2 value, as seen in Table 3 . The contributions in explaining glycemia by the additions of the C-peptide timing indices should be considered in the context of the low range of C-peptide values at the diagnosis of T1D. Those indices help to discern even subtle changes of C-peptide in that range.
Although such changes might be small in overall magnitude, they could have a substantial influence on glycemia.
Other studies such as The Environmental Determinants of Diabe- 
